Antibiotherapy - Page 6 de 7

info-atbvac > International News > Antibiotherapy

Pseudomonas aeruginosa Bloodstream Infections: a short-course of antibiotic therapy is possible if the source of infection is controlled. ( Fabre V. et al. )

Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long is Long Enough?

03 déc | Dr Philippe Lesprit

A randomized controlled trial including 604 patients with gram-negative bloodstream infections (BSI) – including both Enterobacteriaceae and glucose non-fermenting gram-negative … Suite

Amoxicillin/cefazolin, an alternative to amoxicillin/ceftriaxone against endocarditis associated E. faecalis ? An in vitro response. ( Peiffer-Smadja N. et al. )

In vitro bactericidal activity of amoxicillin combined with different cephalosporins against endocarditis-associated Enterococcus faecalis clinical isolates.

26 nov | Dr Jean-Pierre Bru

Synergy between third-generation cephalosporins (TGCs) and ampicillin was discovered in 1995 by Mainardi et al. and then confirmed in many … Suite

Effective combination therapy does not seem to provide any benefit for the treatment of Stenotrophomonas maltophilia pneumonia. ( Shah MD. et al. )

Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia.

21 nov | Dr Olivier Leroy

Stenotrophomonas maltophilia is an emerging nosocomial pathogen more and more often responsible for respiratory tract infections. It is intrinsically resistant … Suite

Which pharmacodynamics targets for β-lactam in Gram-negative bloodstream infections in the critically ill ? ( G. Wong et al. )

β-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill.

13 nov | Dr Jean-Pierre Bru

The objective was to better determine the β-lactam exposure associated with positive clinical outcomes for Gram-negative blood stream infection (BSI) … Suite

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia. Results of a phase 3 trial. ( Kollef MH. et al. )

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.

07 nov | Dr Jean-Pierre Bru

This randomised, controlled, double-blind, non-inferiority trial was conducted at 263 hospitals in 34 countries. Eligible patients were adults, undergoing mechanical … Suite

A robust test to detect the risk of DRESS syndrome under vancomycin. ( Konvinse KC. et al. )

HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms

04 nov | Pr Pierre Tattevin

Vancomycin has been associated with DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms), a rare but potentially fatal hypersensitivity … Suite

Evaluation of a molecular point-of-care testing for viral and atypical pathogens in lower respiratory tract infection: results of a randomized clinical trial ( D. Shengchen et al )

Evaluation of a molecular point-of-care testing for viral and atypical pathogens on intravenous antibiotic duration in hospitalized adults with lower respiratory tract infection: a randomized clinical trial

31 oct | Dr Jean-Pierre Bru

The aim of this study (conducted in Beijing) was to evaluate whether combination of point-of-care test (POCT) and routine real-time … Suite

Treatment of Mycoplasma genitalium infection: efficacy of a resistance-guided strategy using doxycycline-moxifloxacin or doxycycline-azithromycin. ( Durukan D. et al. )

Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability.

29 oct | Dr Jean-Pierre Bru

Macrolide-resistance in Mycoplasma genitalium (MG) exceeds 50% in many regions and quinolone-resistance is increasing. The aim of the study was … Suite

Daptomycin for treatment of gram-positive endocarditis ( Russo A. et al. )

Daptomycin-containing regimens for treatment of gram-positive endocarditis

24 oct | Dr Jean-Pierre Bru

Daptomycin has interesting microbiological and PKPD characteristics for the treatment of gram+ Infectious Endocarditis (IE). This work provides an experience … Suite

Ceftazidime-avibactam: monotherapy or combination therapy to treat carbapenem resistant gram-negative infections ? ( Onorato L. et al. )

Efficacy of ceftazidime-avibactam in monotherapy or combination therapy against carbapenem resistant gram negative organisms: a meta-analysis

18 oct | Dr Jean-Pierre Bru

Ceftazidime/avibactam, display in vitro activity against strains producing class-A-carbapenemases, including Klebsiella pneumoniae (KPC), as well as some class-D-carbapenemases, Some recent … Suite